Veronique R. De Jager
Cape Town, WC, South Africa
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 26 publications
Modeling Treatment Response in Tuberculosis Early Bactericidal Activity Trials.
Journal: CPT: pharmacometrics & systems pharmacology
Published: January 16, 2026
Telacebec, a Potent Agent in the Fight against Tuberculosis: Findings from a Randomized, Phase 2 Clinical Trial and Beyond.
Journal: American journal of respiratory and critical care medicine
Published: March 21, 2025
A Phase 2a Study of the Early Bactericidal Activity of Rifampicin in Combination With Meropenem Plus Amoxicillin/Clavulanate Among Adults With Rifampicin-Resistant Pulmonary Tuberculosis.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: November 13, 2024
Population pharmacokinetics and exposure-response relationship of the antituberculosis drug BTZ-043.
Population pharmacokinetics and exposure-response relationship of the antituberculosis drug BTZ-043.
Journal: The Journal of antimicrobial chemotherapy
Published: October 04, 2024
Safety, pharmacokinetics, and early bactericidal activity of quabodepistat in combination with delamanid, bedaquiline, or both in adults with pulmonary tuberculosis: a randomised, active-controlled, open-label trial.
Journal: The Lancet. Infectious diseases
Published: April 26, 2024
High-Dose Isoniazid Lacks EARLY Bactericidal Activity against Isoniazid-resistant Tuberculosis Mediated by katG Mutations: A Randomized Phase II Clinical Trial.
Journal: American journal of respiratory and critical care medicine
Published: April 02, 2024
Safety and immunogenicity of DNA omicron booster Alveavax-v1.2 in Ad26.COV2.S-vaccinated adults.
Journal: iScience
Published: November 02, 2023
Safety, bactericidal activity, and pharmacokinetics of the antituberculosis drug candidate BTZ-043 in South Africa (PanACEA-BTZ-043-02): an open-label, dose-expansion, randomised, controlled, phase 1b/2a trial.
Journal: The Lancet. Microbe
Published: October 26, 2023
Cough as Noninvasive Biomarker for Monitoring Tuberculosis Treatment: A Proof-of-Concept Study.
Journal: Annals of the American Thoracic Society
Published: September 26, 2023
A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial.
Journal: Nature medicine
Published: June 08, 2023
Phase I Single Ascending Dose and Food Effect Study in Healthy Adults and Phase I/IIa Multiple Ascending Dose Study in Patients with Pulmonary Tuberculosis to Assess Pharmacokinetics, Bactericidal Activity, Tolerability, and Safety of OPC-167832.
Journal: Antimicrobial agents and chemotherapy
Published: May 23, 2023
Last Updated: 09/26/2026